Ansheng Medical Completes Tens of Millions RMB Series A Financing to Accelerate Expansion in Minimally Invasive Oncology, HAOYUE CAPITAL Acts as Exclusive Financial Advisor

Recently, Ansheng Medical and Yida Capital held a strategic cooperation signing ceremony in Nanjing. Attendees included Shi Yunzhong, Founder of Yida Capital; Ren Zhenghua, Investment Director at Yida Project; Xiao Lijian, Founder of Yunyeyuan Investment; Chen Zhiming, Founder of Ansheng Medical; Xie Dan, CEO of Ansheng Medical; Ding Yameng, Partner at Haoyue Capital; and other senior executives from the respective organizations.

At the conference, Ansheng Medical announced the completion of its Series A financing round, amounting to tens of millions of RMB. The round was led by Yida Capital, with participation from Yunyeyuan Capital, while Haoyue Capital served as the exclusive financial advisor for this financing round. Following the financing, Ansheng Medical will enter a phase of rapid development and platform expansion.

At the meeting, Chen Zhiming stated, “I would like to thank all investors and the management team of Ansheng for their trust in me. With the completion of our Series A financing, the company has reached a new platform and a fresh starting point. We will continue to move forward with the support and confidence of our investors, striving to become a leader in the field of minimally invasive medical technology.”

Ansheng Medical Devices (Nanjing) Co., Ltd. is a leading domestic company with a full industry chain covering minimally invasive oncology, minimally invasive surgery, and other fields. For many years, it has served as the exclusive general agent in China for tumor radiofrequency ablation products from AngioDynamics (USA) and EMcision (UK), and has established a market sales channel and network covering hospitals at all levels across China.

Among these, AngioDynamics’ RITA radiofrequency ablation (RFA) products represent advanced technology and set a benchmark in the global field of tumor RFA therapy. They are now widely used in the treatment of various solid tumors. In particular, their multipolar needle features an anchor-like design that produces ablation zones closely approximating a spherical shape, establishing them as an industry benchmark for core metrics such as therapeutic efficacy and safety. The RITA system currently boasts the lowest post-treatment recurrence rate among tumor ablation systems worldwide.

In response to national strategic initiatives and policies, and to support the development of domestically produced medical equipment and devices, Ansheng Company commenced independent research and development, registration, and manufacturing in 2013 for a range of products including radiofrequency and microwave ablation needles, ablation therapy systems, and ultrasonic scalpels. The company has developed ablation technologies for indications such as lung cancer, thyroid disorders, and breast conditions, and has produced new, safe, reliable, and user-friendly ablation systems and ancillary devices, which have received recognition and approval from the National Medical Products Administration (NMPA).
 
In addition, Ansheng has introduced multiple internationally leading medical products and technologies to China through various forms of international cooperation, including: the EMcision radiofrequency ablation catheter series for the treatment of luminal tumors and biliary obstruction; the Habib 4X coagulation electrode for surgical hemostasis and resection; the ISYS intelligent navigation system for minimally invasive surgical localization; and the F-care radiofrequency thermal coagulation system, which is effectively used in the treatment of varicose veins. Ansheng Medical has established a technology R&D center in California, USA, and entered into strategic collaborations with several technologically advanced innovative medical device companies in Europe. By integrating global leading innovative perspectives and cutting-edge technologies with domestic teams possessing extensive R&D experience and clinical product expertise, Ansheng is committed to becoming a leading pioneer in technology and products within the domestic minimally invasive medical field.

Shi Yunzhong, Founding Partner of Yida Capital, believes that minimally invasive surgery represents a significant future trend in surgical treatment, and Yida Capital is highly optimistic about the market development in this sector. Ansheng Medical boasts a team with extensive experience in industrial and capital operations, has initially established specialized R&D and marketing platforms, and possesses sustained capabilities for introducing and commercializing international products. Yida Capital’s lead investment in Ansheng Medical marks a strategic focus in the field of minimally invasive surgery. Through this investment, Yida Capital aims to facilitate the company’s growth and achieve mutual benefits through the synergy of capital and industry.

Mr. Xiao Lijian, Founder of Yunyeyuan Investment, stated that by combining advanced overseas technologies with the vast domestic market, Ansheng Medical’s strategy of starting as a distributor of imported products and transitioning toward replacing imported medical devices with domestically produced ones is the right direction. Yunyeyuan has strong confidence in the future development of Ansheng Medical.

Mr. Ding Yameng, Founding Partner of Haoyue Capital, stated that the global market for minimally invasive oncology is projected to exceed $50 billion in the coming years. Haoyue Capital holds a highly positive outlook on the development of the minimally invasive medical market. By continuously building an experienced and high-execution team and introducing internationally leading technologies and products, Ansheng Medical is poised to become a leading brand in China’s minimally invasive medical sector.

【Introduction to Ansheng Medical】
Shengyuan Weichuang is a leading domestic company with comprehensive operations in the minimally invasive field, covering areas such as minimally invasive oncology and minimally invasive surgery. As the exclusive distributor in China for tumor radiofrequency minimally invasive products from US-based AngioDynamics and UK-based EMcision, the company has established a marketing and sales network spanning hospitals at all levels across China. Building on this foundation, it has initiated the research, development, and production of several proprietary products, including radiofrequency and microwave ablation needles and ablation therapy systems.

In the future, the Company will continue to enrich its product portfolio with minimally invasive medical solutions at its core, and work closely with multiple international partners to build a leading Chinese innovation platform for minimally invasive medicine.

[Introduction to Yida Capital]
Yida Capital was established through mixed-ownership reform within Jiangsu High-Tech Investment Group, a long-established state-owned venture capital firm in China. It is one of the most influential venture capital institutions in the country, boasting the strongest industry research capabilities, the highest level of investment specialization, and the largest assets under management.

Yida Capital’s management team has been engaged in investment operations since 1992. To date, it has established 76 equity investment funds with diverse strategic focuses, managing over RMB 80 billion in capital. The firm has cumulatively invested in and supported nearly 700 startups, helping 125 of them successfully list on domestic and international capital markets.

[Profile of Yunyeyuan Investment]
Yun Yeyuan Investment is an investment firm specializing in equity investments in high-growth enterprises within the high-tech sector, as well as IPO planning and capital operations. The company’s management team boasts distinguished educational backgrounds from both domestic and international institutions, along with extensive professional experience in the securities and fund industries.

[About Haoyue Capital]
Haoyue Capital was established in June 2013, specializing in providing comprehensive capital solutions to leading enterprises in China’s healthcare industry. The team comprises seasoned investment bankers and professionals from the Chinese healthcare sector.

Since its inception, Haoyue Capital has successfully completed 45 private equity financing and M&A projects in the healthcare sector, with total transaction value approaching $1 billion, ranking first in China by deal count.